BioNexus Gene Lab Corp. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
BioNexus Gene Lab Corp. (BGLC) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-05-15
- BioNexus Gene Lab Corp. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $0.00.
- BioNexus Gene Lab Corp. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-03-31 was $55.75K, a 184.48% increase year-over-year.
- BioNexus Gene Lab Corp. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $24.67K.
- BioNexus Gene Lab Corp. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was -$2.39K.
- BioNexus Gene Lab Corp. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $215.24K.
- BioNexus Gene Lab Corp. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $23.54K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 24 month |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | $0.00 10-Q · filed 2026-05-15 | $177.74K 10-K · filed 2026-04-14 | ||||
| 2024-12-31 | $215.24K 10-K · filed 2026-04-14 | |||||
| 2021-09-30 | $15.84K 10-Q · filed 2021-11-15 | |||||
| 2021-03-31 | $55.75K 10-Q · filed 2021-05-18 | $80.42K derived: sum of 2 quarters · filed 2021-11-15 | $78.03K derived: sum of 3 quarters · filed 2021-11-15 | $75.08K derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-12-31 | $24.67K derived: 10-Q 12 month − 10-Q/A 9 month · filed 2021-11-15 | $22.29K derived: sum of 2 quarters · filed 2021-11-15 | $19.34K derived: sum of 3 quarters · filed 2021-11-15 | $38.93K 10-Q · filed 2021-11-15 | $65.53K 10-K · filed 2021-03-30 | |
| 2020-09-30 | -$2.39K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2020-11-09 | -$5.34K derived: sum of 2 quarters · filed 2020-11-09 | $14.26K 10-Q/A · filed 2020-11-09 | |||
| 2020-06-30 | -$2.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $16.64K 10-Q · filed 2020-08-11 | ||||
| 2020-03-31 | $19.60K 10-Q · filed 2020-05-08 | |||||
| 2019-12-31 | $23.54K 10-K · filed 2021-03-30 | $23.54K 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |